{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:05:27Z","timestamp":1782277527686,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019871","name":"Castle Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-024-03512-4","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:03:07Z","timestamp":1724997787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Integrating the melanoma 31-gene expression profile test with clinical and pathologic features can provide personalized precision estimates for sentinel lymph node positivity: an independent performance cohort"],"prefix":"10.1186","volume":"22","author":[{"given":"Chase","family":"Kriza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"7","key":"3512_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609.","journal-title":"N Engl J Med"},{"key":"3512_CR2","unstructured":"Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF et al. Therapeutic value of sentinel lymph node biopsy in patients with melanoma: a randomized clinical trial. JAMA Surg. 2022 [cited 2022 Aug 9]. https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2794852"},{"issue":"29","key":"3512_CR3","doi-asserted-by":"publisher","first-page":"45671","DOI":"10.18632\/oncotarget.10140","volume":"7","author":"J Chen","year":"2016","unstructured":"Chen J, Xu Y, Zhou Y, Wang Y, Zhu H, Shi Y. Prognostic role of sentinel lymph node biopsy for patients with cutaneous melanoma: a retrospective study of surveillance, epidemiology, and end-result population-based data. Oncotarget. 2016;7(29):45671\u20137.","journal-title":"Oncotarget"},{"issue":"1","key":"3512_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/jso.26225","volume":"123","author":"TJ Aiken","year":"2021","unstructured":"Aiken TJ, Stahl CC, Schwartz PB, et al. Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma. J Surg Oncol. 2021;123(1):104\u20139.","journal-title":"J Surg Oncol"},{"key":"3512_CR5","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cutaneous melanoma 2024. 2024 [cited 2024 May 7]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"key":"3512_CR6","doi-asserted-by":"crossref","unstructured":"Maddineni S, Dizon MP, Muralidharan V, et al. Validation of the Melanoma Institute of Australia\u2019s sentinel lymph node biopsy risk prediction tool for cutaneous melanoma. Ann Surg Oncol. 2024;31(4):2737\u201346.","DOI":"10.1245\/s10434-023-14862-w"},{"key":"3512_CR7","unstructured":"Bagge RO, Mikiver R, Marchetti MA, et al. Population-based validation of the MIA and MSKCC tools for predicting sentinel lymph node status. JAMA Surg. 2024;e236904."},{"issue":"1","key":"3512_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/XCS.0000000000000886","volume":"238","author":"HM Drebin","year":"2024","unstructured":"Drebin HM, Hosein S, Kurtansky NR, et al. Clinical utility of melanoma sentinel lymph node biopsy nomograms. J Am Coll Surg. 2024;238(1):23\u201331.","journal-title":"J Am Coll Surg"},{"issue":"3","key":"3512_CR9","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/jso.26723","volume":"125","author":"MB Weitemeyer","year":"2022","unstructured":"Weitemeyer MB, Helvind NM, Brinck AM, H\u00f6lmich LR, Chakera AH. More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: a Danish population-based study of 7148 patients. J Surg Oncol. 2022;125(3):498\u2013508.","journal-title":"J Surg Oncol"},{"issue":"4","key":"3512_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.jamcollsurg.2018.12.030","volume":"228","author":"ME Egger","year":"2019","unstructured":"Egger ME, Stevenson M, Bhutiani N, et al. Should sentinel lymph node biopsy be performed for all T1b melanomas in the new 8th edition American Joint Committee on cancer staging system? J Am Coll Surg. 2019;228(4):466\u201372.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"3512_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jaad.2018.08.051","volume":"80","author":"RRZ Conic","year":"2019","unstructured":"Conic RRZ, Ko J, Damiani G, et al. Predictors of sentinel lymph node positivity in thin melanoma using the national cancer database. J Am Acad Dermatol. 2019;80(2):441\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"3512_CR12","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1200\/JCO.2013.54.2340","volume":"32","author":"A Maurichi","year":"2014","unstructured":"Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. J Clin Oncol. 2014;32(23):2479\u201385.","journal-title":"J Clin Oncol"},{"issue":"5","key":"3512_CR13","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.jaad.2017.11.041","volume":"78","author":"L Wheless","year":"2018","unstructured":"Wheless L, Isom CA, Hooks MA, Kauffmann RM. Mitotic rate is associated with positive lymph nodes in thin melanomas. J Am Acad Dermatol. 2018;78(5):935\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"3512_CR14","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1002\/cam4.2358","volume":"8","author":"A Tejera-Vaquerizo","year":"2019","unstructured":"Tejera-Vaquerizo A, Ribero S, Puig S, et al. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: a multicenter observational study. Cancer Med. 2019;8(9):4235\u201344.","journal-title":"Cancer Med"},{"key":"3512_CR15","doi-asserted-by":"crossref","unstructured":"Shannon AB, Wood C, Straker RJ, et al. Age and mitogenicity are important predictors of sentinel lymph node metastasis in T1a melanoma. Ann Surg Oncol. 2021;28(9):4777\u20139.","DOI":"10.1245\/s10434-021-09929-5"},{"key":"3512_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1200\/PO.21.00162","volume":"5","author":"ED Whitman","year":"2021","unstructured":"Whitman ED, Koshenkov VP, Gastman BR, et al. Integrating 31-gene expression profiling with clinicopathologic features to optimize cutaneous melanoma sentinel lymph node metastasis prediction. JCO Precision Oncol. 2021;5:1466\u201379.","journal-title":"JCO Precision Oncol"},{"issue":"6","key":"3512_CR17","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.jaad.2022.06.1202","volume":"87","author":"A Jarell","year":"2022","unstructured":"Jarell A, Gastman BR, Dillon LD, et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test. J Am Acad Dermatol. 2022;87(6):1312\u201320.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"3512_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1200\/PO.20.00119","volume":"5","author":"EC Hsueh","year":"2021","unstructured":"Hsueh EC, DeBloom JR, Lee JH, et al. Long-term outcomes in a multicenter, prospective cohort evaluating the prognostic 31-gene expression profile for cutaneous melanoma. JCO Precision Oncol. 2021;5(5):589\u2013601.","journal-title":"JCO Precision Oncol"},{"issue":"11","key":"3512_CR19","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/fon-2018-0912","volume":"15","author":"JT Vetto","year":"2019","unstructured":"Vetto JT, Hsueh EC, Gastman BR, et al. Guidance of sentinel lymph node biopsy decisions in patients with T1\u2013T2 melanoma using gene expression profiling. Future Oncol. 2019;15(11):1207\u201317.","journal-title":"Future Oncol"},{"issue":"6","key":"3512_CR20","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.amjsurg.2021.03.028","volume":"221","author":"SP Arnot","year":"2021","unstructured":"Arnot SP, Han G, Fortino J, Han D, Fowler G, Vetto JT. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. Am J Surg. 2021;221(6):1195\u20139.","journal-title":"Am J Surg"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-024-03512-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-024-03512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:04:51Z","timestamp":1724997891000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-024-03512-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3512"],"URL":"https:\/\/doi.org\/10.1186\/s12957-024-03512-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"15 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a retrospective chart review and received IRB approval for a consent waiver.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"BM and CNB are employees and options\/stock holders of Castle Biosciences, Inc. CK and JB have no relevant conflicts.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}